Related Experiment Video
Updated: Apr 24, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Dyslipidaemia: cardiovascular prevention--end of the road for niacin?
1Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 11-125 Smilow Centre for Translational Research, 3400 Civic Centre Blvd, Philadelphia, PA 19104, USA.
Abstract:
The recently published HPS2–THRIVE study has shown that the addition of extended release niacin to statin therapy in patients with well-controlled levels of LDL cholesterol does not reduce the risk of cardiovascular events and might even increase harm. Consequently, the use of niacin to increase levels of HDL cholesterol is not recommended.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Lipids: Dietary Sources and Requirements
Angina IV: Management
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

